Document:

APPENDIX B

          NEVADA REVISED STATUTES - SECTIONS 92A.300 - 92A.500
                      RIGHTS OF DISSENTING OWNERS

NRS 92A.300 Definitions.
As used in NRS 92A.300 to 92A.500, inclusive, unless the context
otherwise requires, the words and terms defined in NRS 92A.305 to
92A.335, inclusive, have the meanings ascribed to them in those
sections.  (Added to NRS by 1995, 2086)

NRS 92A.305 "Beneficial stockholder" defined.
"Beneficial stockholder" means a person who is a beneficial owner of
shares held in a voting trust or by a nominee as the stockholder of
record.  (Added to NRS by 1995, 2087)

NRS 92A.310 "Corporate action" defined.
"Corporate action" means the action of a domestic corporation.  (Added
to NRS by 1995, 2087)

NRS 92A.315 "Dissenter" defined.
"Dissenter" means a stockholder who is entitled to dissent from a
domestic corporation's action under NRS 92A.380 and who exercises that
right when and in the manner required by NRS 92A.400 to 92A.480,
inclusive.  (Added to NRS by 1995, 2087; A 1999, 1631)

NRS 92A.320 "Fair value" defined.
"Fair value," with respect to a dissenter's shares, means the value of
the shares immediately before the effectuation of the corporate action
to which he objects, excluding any appreciation or depreciation in
anticipation of the corporate action unless exclusion would be
inequitable.  (Added to NRS by 1995, 2087)

NRS 92A.325 "Stockholder" defined.
"Stockholder" means a stockholder of record or a beneficial stockholder
of a domestic corporation.  (Added to NRS by 1995, 2087)

NRS 92A.330 "Stockholder of record" defined.
"Stockholder of record" means the person in whose name shares are
registered in the records of a domestic corporation or the beneficial
owner of shares to the extent of the rights granted by a nominee's
certificate on file with the domestic corporation.  (Added to NRS by
1995, 2087)

NRS 92A.335 "Subject corporation" defined.
"Subject corporation" means the domestic corporation which is the
issuer of the shares held by a dissenter before the corporate action
creating the dissenter's rights becomes effective or the surviving or
acquiring entity of that issuer after the corporate action becomes
effective.  (Added to NRS by 1995, 2087)

NRS 92A.340 Computation of interest.
Interest payable pursuant to NRS 92A.300 to 92A.500, inclusive, must be
computed from the effective date of the action until the date of
payment, at the average rate currently paid by the entity on its

<PAGE>2

principal bank loans or, if it has no bank loans, at a rate that is
fair and equitable under all of the circumstances. (Added to NRS by
1995, 2087)

RS 92A.350 Rights of dissenting partner of domestic limited
partnership.
A partnership agreement of a domestic limited partnership or, unless
otherwise provided in the partnership agreement, an agreement of merger
or exchange, may provide that contractual rights with respect to the
partnership interest of a dissenting general or limited partner of a
domestic limited partnership are available for any class or group of
partnership interests in connection with any merger or exchange in
which the domestic limited partnership is a constituent entity.  (Added
to NRS by 1995, 2088)

NRS 92A.360 Rights of dissenting member of domestic limited-liability
company.
The articles of organization or operating agreement of a domestic
limited-liability company or, unless otherwise provided in the articles
of organization or operating agreement, an agreement of merger or
exchange, may provide that contractual rights with respect to the
interest of a dissenting member are available in connection with any
merger or exchange in which the domestic limited-liability company is a
constituent entity.  (Added to NRS by 1995, 2088)

NRS 92A.370 Rights of dissenting member of domestic nonprofit
corporation.
1.  Except as otherwise provided in subsection 2, and unless otherwise
provided in the articles or bylaws, any member of any constituent
domestic nonprofit corporation who voted against the merger may,
without prior notice, but within 30 days after the effective date of
the merger, resign from membership and is thereby excused from all
contractual obligations to the constituent or surviving corporations
which did not occur before his resignation and is thereby entitled to
those rights, if any, which would have existed if there had been no
merger and the membership had been terminated or the member had been
expelled.
2.  Unless otherwise provided in its articles of incorporation or
bylaws, no member of a domestic nonprofit corporation, including, but
not limited to, a cooperative corporation, which supplies services
described in chapter 704 of NRS to its members only, and no person who
is a member of a domestic nonprofit corporation as a condition of or by
reason of the ownership of an interest in real property, may resign and
dissent pursuant to subsection 1.
(Added to NRS by 1995, 2088)

NRS 92A.380 Right of stockholder to dissent from certain corporate
actions and to obtain payment for shares.

1.  Except as otherwise provided in NRS 92A.370 and 92A.390, any
stockholder is entitled to dissent from, and obtain payment of the fair
value of his shares in the event of any of the following corporate
actions:

<PAGE>3

  (a)  Consummation of a conversion or plan of merger to which the
domestic corporation is a constituent entity:
       (1)  If approval by the stockholders is required for the
conversion or merger by NRS 92A.120 to 92A.160, inclusive, or the
articles of incorporation, regardless of whether the stockholder is
entitled to vote on the conversion or plan of merger; or
       (2)  If the domestic corporation is a subsidiary and is merged
with its parent pursuant to NRS 92A.180.
  (b)  Consummation of a plan of exchange to which the domestic
corporation is a constituent entity as the corporation whose subject
owner's interests will be acquired, if his shares are to be acquired in
the plan of exchange.
  (c)  Any corporate action taken pursuant to a vote of the
stockholders to the extent that the articles of incorporation, bylaws
or a resolution of the board of directors provides that voting or
nonvoting stockholders are entitled to dissent and obtain payment for
their shares.
2.  A stockholder who is entitled to dissent and obtain payment
pursuant to NRS 92A.300 to 92A.500, inclusive, may not challenge the
corporate action creating his entitlement unless the action is unlawful
or fraudulent with respect to him or the domestic corporation.
(Added to NRS by 1995, 2087; A 2001, 1414, 3199; 2003, 3189)

NRS 92A.390 Limitations on right of dissent: Stockholders of certain
classes or series; action of stockholders not required for plan of
merger.
1.  There is no right of dissent with respect to a plan of merger or
exchange in favor of stockholders of any class or series which, at the
record date fixed to determine the stockholders entitled to receive
notice of and to vote at the meeting at which the plan of merger or
exchange is to be acted on, were either listed on a national securities
exchange, included in the national market system by the National
Association of Securities Dealers, Inc., or held by at least 2,000
stockholders of record, unless:
  (a)  The articles of incorporation of the corporation issuing the
shares provide otherwise; or
  (b)  The holders of the class or series are required under the plan
of merger or exchange to accept for the shares anything except:
       (1)  Cash, owner's interests or owner's interests and cash in
lieu of fractional owner's interests of:
          (I)  The surviving or acquiring entity; or
         (II)  Any other entity which, at the effective date of the
plan of merger or exchange, were either listed on a national securities
exchange, included in the national market system by the National
Association of Securities Dealers, Inc., or held of record by a least
2,000 holders of owner's interests of record; or
       (2)  A combination of cash and owner's interests of the kind
described in sub-subparagraphs (I) and (II) of subparagraph (1) of
paragraph (b).
2.  There is no right of dissent for any holders of stock of the
surviving domestic corporation if the plan of merger does not require
action of the stockholders of the surviving domestic corporation under
NRS 92A.130.
(Added to NRS by 1995, 2088)

<PAGE>4

NRS 92A.400 Limitations on right of dissent: Assertion as to portions
only to shares registered to stockholder; assertion by beneficial
stockholder.
1.  A stockholder of record may assert dissenter's rights as to fewer
than all of the shares registered in his name only if he dissents with
respect to all shares beneficially owned by any one person and notifies
the subject corporation in writing of the name and address of each
person on whose behalf he asserts dissenter's rights. The rights of a
partial dissenter under this subsection are determined as if the shares
as to which he dissents and his other shares were registered in the
names of different stockholders.
2.  A beneficial stockholder may assert dissenter's rights as to shares
held on his behalf only if:
  (a)  He submits to the subject corporation the written consent of the
stockholder of record to the dissent not later than the time the
beneficial stockholder asserts dissenter's rights; and
  (b)  He does so with respect to all shares of which he is the
beneficial stockholder or over which he has power to direct the vote.
(Added to NRS by 1995, 2089)

NRS 92A.410 Notification of stockholders regarding right of dissent.
1.  If a proposed corporate action creating dissenters' rights is
submitted to a vote at a stockholders' meeting, the notice of the
meeting must state that stockholders are or may be entitled to assert
dissenters' rights under NRS 92A.300 to 92A.500, inclusive, and be
accompanied by a copy of those sections.
2.  If the corporate action creating dissenters' rights is taken by
written consent of the stockholders or without a vote of the
stockholders, the domestic corporation shall notify in writing all
stockholders entitled to assert dissenters' rights that the action was
taken and send them the dissenter's notice described in NRS 92A.430.
(Added to NRS by 1995, 2089; A 1997, 730)

NRS 92A.420 Prerequisites to demand for payment for shares.
1.  If a proposed corporate action creating dissenters' rights is
submitted to a vote at a stockholders' meeting, a stockholder who
wishes to assert dissenter's rights:
  (a)  Must deliver to the subject corporation, before the vote is
taken, written notice of his intent to demand payment for his shares if
the proposed action is effectuated; and
  (b)  Must not vote his shares in favor of the proposed action.
2.  A stockholder who does not satisfy the requirements of subsection 1
and NRS 92A.400 is not entitled to payment for his shares under this
chapter.
(Added to NRS by 1995, 2089; 1999, 1631)

NRS 92A.430 Dissenter's notice: Delivery to stockholders entitled to
assert rights; contents.
1.  If a proposed corporate action creating dissenters' rights is
authorized at a stockholders' meeting, the subject corporation shall
deliver a written dissenter's notice to all stockholders who satisfied
the requirements to assert those rights.
2.  The dissenter's notice must be sent no later than 10 days after the
effectuation of the corporate action, and must:

<PAGE>5

  (a)  State where the demand for payment must be sent and where and
when certificates, if any, for shares must be deposited;
  (b)  Inform the holders of shares not represented by certificates to
what extent the transfer of the shares will be restricted after the
demand for payment is received;
  (c)  Supply a form for demanding payment that includes the date of
the first announcement to the news media or to the stockholders of the
terms of the proposed action and requires that the person asserting
dissenter's rights certify whether or not he acquired beneficial
ownership of the shares before that date;
  (d)  Set a date by which the subject corporation must receive the
demand for payment, which may not be less than 30 nor more than 60 days
after the date the notice is delivered; and
  (e)  Be accompanied by a copy of NRS 92A.300 to 92A.500, inclusive.
(Added to NRS by 1995, 2089)

NRS 92A.440 Demand for payment and deposit of certificates; retention
of rights of stockholder.
1.  A stockholder to whom a dissenter's notice is sent must:
  (a)  Demand payment;
  (b)  Certify whether he or the beneficial owner on whose behalf he is
dissenting, as the case may be, acquired beneficial ownership of the
shares before the date required to be set forth in the dissenter's
notice for this certification; and
  (c)  Deposit his certificates, if any, in accordance with the terms
of the notice.

2.  The stockholder who demands payment and deposits his certificates,
if any, before the proposed corporate action is taken retains all other
rights of a stockholder until those rights are cancelled or modified by
the taking of the proposed corporate action.
3.  The stockholder who does not demand payment or deposit his
certificates where required, each by the date set forth in the
dissenter's notice, is not entitled to payment for his shares under
this chapter.
(Added to NRS by 1995, 2090; A 1997, 730; 2003, 3189)

NRS 92A.450 Uncertificated shares: Authority to restrict transfer after
demand for payment; retention of rights of stockholder.
1.  The subject corporation may restrict the transfer of shares not
represented by a certificate from the date the demand for their payment
is received.
2.  The person for whom dissenter's rights are asserted as to shares
not represented by a certificate retains all other rights of a
stockholder until those rights are cancelled or modified by the taking
of the proposed corporate action.
(Added to NRS by 1995, 2090)

NRS 92A.460 Payment for shares: General requirements.
1.  Except as otherwise provided in NRS 92A.470, within 30 days after
receipt of a demand for payment, the subject corporation shall pay each
dissenter who complied with NRS 92A.440 the amount the subject
corporation estimates to be the fair value of his shares, plus accrued
interest. The obligation of the subject corporation under this
subsection may be enforced by the district court:

<PAGE>6

  (a)  Of the county where the corporation's registered office is
located; or
  (b)  At the election of any dissenter residing or having its
registered office in this state, of the county where the dissenter
resides or has its registered office. The court shall dispose of the
complaint promptly.
2.  The payment must be accompanied by:
  (a)  The subject corporation's balance sheet as of the end of a
fiscal year ending not more than 16 months before the date of payment,
a statement of income for that year, a statement of changes in the
stockholders' equity for that year and the latest available interim
financial statements, if any;
  (b)  A statement of the subject corporation's estimate of the fair
value of the shares;
  (c)  An explanation of how the interest was calculated;
  (d)  A statement of the dissenter's rights to demand payment under
NRS 92A.480; and
  (e)  A copy of NRS 92A.300 to 92A.500, inclusive.
(Added to NRS by 1995, 2090)

NRS 92A.470 Payment for shares: Shares acquired on or after date of
dissenter's notice.
1.  A subject corporation may elect to withhold payment from a
dissenter unless he was the beneficial owner of the shares before the
date set forth in the dissenter's notice as the date of the first
announcement to the news media or to the stockholders of the terms of
the proposed action.
2.  To the extent the subject corporation elects to withhold payment,
after taking the proposed action, it shall estimate the fair value of
the shares, plus accrued interest, and shall offer to pay this amount
to each dissenter who agrees to accept it in full satisfaction of his
demand. The subject corporation shall send with its offer a statement
of its estimate of the fair value of the shares, an explanation of how
the interest was calculated, and a statement of the dissenters' right
to demand payment pursuant to NRS 92A.480.
(Added to NRS by 1995, 2091)

NRS 92A.480 Dissenter's estimate of fair value: Notification of subject
corporation; demand for payment of estimate.
1.  A dissenter may notify the subject corporation in writing of his
own estimate of the fair value of his shares and the amount of interest
due, and demand payment of his estimate, less any payment pursuant to
NRS 92A.460, or reject the offer pursuant to NRS 92A.470 and demand
payment of the fair value of his shares and interest due, if he
believes that the amount paid pursuant to NRS 92A.460 or offered
pursuant to NRS 92A.470 is less than the fair value of his shares or
that the interest due is incorrectly calculated.
2.  A dissenter waives his right to demand payment pursuant to this
section unless he notifies the subject corporation of his demand in
writing within 30 days after the subject corporation made or offered
payment for his shares.
(Added to NRS by 1995, 2091)

<PAGE>7

NRS 92A.490 Legal proceeding to determine fair value: Duties of subject
corporation; powers of court; rights of dissenter.
1.  If a demand for payment remains unsettled, the subject corporation
shall commence a proceeding within 60 days after receiving the demand
and petition the court to determine the fair value of the shares and
accrued interest. If the subject corporation does not commence the
proceeding within the 60-day period, it shall pay each dissenter whose
demand remains unsettled the amount demanded.
2.  A subject corporation shall commence the proceeding in the district
court of the county where its registered office is located. If the
subject corporation is a foreign entity without a resident agent in the
state, it shall commence the proceeding in the county where the
registered office of the domestic corporation merged with or whose
shares were acquired by the foreign entity was located.
3.  The subject corporation shall make all dissenters, whether or not
residents of Nevada, whose demands remain unsettled, parties to the
proceeding as in an action against their shares. All parties must be
served with a copy of the petition. Nonresidents may be served by
registered or certified mail or by publication as provided by law.
4.  The jurisdiction of the court in which the proceeding is commenced
under subsection 2 is plenary and exclusive. The court may appoint one
or more persons as appraisers to receive evidence and recommend a
decision on the question of fair value. The appraisers have the powers
described in the order appointing them, or any amendment thereto. The
dissenters are entitled to the same discovery rights as parties in
other civil proceedings.
5.  Each dissenter who is made a party to the proceeding is entitled to
a judgment:
  (a)  For the amount, if any, by which the court finds the fair value
of his shares, plus interest, exceeds the amount paid by the subject
corporation; or
  (b)  For the fair value, plus accrued interest, of his after-acquired
shares for which the subject corporation elected to withhold payment
pursuant to NRS 92A.470.
(Added to NRS by 1995, 2091

NRS 92A.500 Legal proceeding to determine fair value: Assessment of
costs and fees.
1.  The court in a proceeding to determine fair value shall determine
all of the costs of the proceeding, including the reasonable
compensation and expenses of any appraisers appointed by the court. The
court shall assess the costs against the subject corporation, except
that the court may assess costs against all or some of the dissenters,
in amounts the court finds equitable, to the extent the court finds the
dissenters acted arbitrarily, vexatiously or not in good faith in
demanding payment.
2.  The court may also assess the fees and expenses of the counsel and
experts for the respective parties, in amounts the court finds
equitable:
  (a)  Against the subject corporation and in favor of all dissenters
if the court finds the subject corporation did not substantially comply
with the requirements of NRS 92A.300 to 92A.500, inclusive; or

<PAGE>8

 (b)  Against either the subject corporation or a dissenter in favor of
any other party, if the court finds that the party against whom the
fees and expenses are assessed acted arbitrarily, vexatiously or not in
good faith with respect to the rights provided by NRS 92A.300 to
92A.500, inclusive.
3.  If the court finds that the services of counsel for any dissenter
were of substantial benefit to other dissenters similarly situated, and
that the fees for those services should not be assessed against the
subject corporation, the court may award to those counsel reasonable
fees to be paid out of the amounts awarded to the dissenters who were
benefited.
4.  In a proceeding commenced pursuant to NRS 92A.460, the court may
assess the costs against the subject corporation, except that the court
may assess costs against all or some of the dissenters who are parties
to the proceeding, in amounts the court finds equitable, to the extent
the court finds that such parties did not act in good faith in
instituting the proceeding.
5.  This section does not preclude any party in a proceeding commenced
pursuant to NRS 92A.460 or 92A.490 from applying the provisions of
N.R.C.P. 68 or NRS 17.115.
(Added to NRS by 1995, 2092)UNITED STATES
                   SECURITIES AND EXCHANGE COMMISSION
                         WASHINGTON, D.C. 20549

                              FORM 10-QSB/A

( X )   Quarterly Report pursuant to Section 13 or 15(d) of the
        Securities Exchange Act of 1934 For the quarterly period ended
        September 30, 2003

(   )   Transition Report pursuant to 13 or 15(d) of the Securities
        Exchange Act of 1934
        For the transition period              to

                 Commission File Number     000-49735

                      INTRAOP MEDICAL CORPORATION
   (Exact name of Small Business Issuer as specified in its charter)

            Nevada                                87-0642947
  (State or other jurisdiction                 (I.R.S. Employer
    of incorporation or                         Identification No.)
        organization)

        7408 Comstock Circle
        Salt Lake City, Utah                        84121
(Address of principal executive offices)          (Zip Code)

  Issuer's telephone number, including
       area code:  801-943-2345

                       (DIGITALPREVIEWS.COM, INC.)
          (Former name, former address and former fiscal year,
                      if changed since last report)

Check whether the issuer (1)filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the issuer was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days  (X) Yes  (  ) No
State the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date:  1,114,200 Shares
of $.001 par value Common Stock outstanding as of September 30, 2003;
20,284,000 Shares of $0.001 par value Common Stock outstanding as of
the date of this filing as result of a share dividend of 20:1 effective
on October 1, 2003.

<PAGE>2
                     PART 1 - FINANCIAL INFORMATION

Item 1.  Financial Statements

The accompanying unaudited financial statements have been prepared in
accordance with the instructions to Form 10-QSB and, therefore, do not
include all information and footnotes necessary for a complete
presentation of financial position, results of operations, cash flows,
and stockholders' deficit in conformity with generally accepted
accounting principles.  In the opinion of management, all adjustments
considered necessary for a fair presentation of the results of
operations and financial position have been included and all such
adjustments are of a normal recurring nature.  Operating results for
the nine months ended September 30, 2003 are not necessarily indicative
of the results that can be expected for the year ending December 31,
2003.

<PAGE>3
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A DEVELOPMENT STAGE COMPANY)
                          FINANCIAL STATEMENTS
                           SEPTEMBER 30, 2003

                              TABLE OF CONTENTS

                                                          Page Number
                                                         -------------
Financial Statements:

    Unaudited Condensed Consolidated Balance Sheet,
      September 30, 2003                                         F - 1

    Unaudited Condensed Consolidated Statements of
     Operations, for the nine months ended September 30,
     2003 and for the period from inception on November 5,
     1999 through September 30, 2003                             F - 2

    Unaudited Condensed Consolidated Statements of
     Stockholders' Equity, for the period from inception
     on November 5, 1999 through September 30, 2003              F - 3

    Unaudited Condensed Consolidated Statements of
     Cash Flows, for the nine months ended September 30,
     2003 and for the period from inception on November 5,
     1999 through September 30, 2003                             F - 4

    Notes to the Financial Statements                            F - 5

<PAGE>4
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A DEVELOPMENT STAGE COMPANY)
                        CONSOLIDATED BALANCE SHEET

                                                         September 30,
ASSETS                                                        2003
  Current Assets
    Cash in bank                                           $    2,506
                                                           ----------
      Total Current Assets                                      2,506
  Other Assets
    Impaired note receivable, net (see Note 3)                      -
    Deferred stock offering costs                              24,742
                                                           ----------
      Total Other Assets                                       24,742
                                                           ----------
          TOTAL ASSETS                                     $   27,248
                                                           ==========

LIABILITIES & STOCKHOLDERS' EQUITY
  Current Liabilities
    Accounts payable                                       $   31,310
    Note payable - shareholder                                  5,000
                                                           ----------
      Total Liabilities                                        36,310

  Stockholders' Equity
    Preferred stock, $.001 par value, 5,000,000 shares
     authorized, no share issued and outstanding                    -
    Common stock, $.001 par value, 50,000,000 shares
     authorized, 1,114,200 shares issued and outstanding        1,114
    Capital in excess of par value                             41,586
    Deficit accumulated during the development stage          (51,762)
                                                           ----------
      Total Stockholders' Equity                               (9,062)
                                                           ----------
          TOTAL LIABILITIES & STOCKHOLDERS' EQUITY         $   27,248
                                                           ==========

The accompanying notes are an integral part of these financial
statements.

<PAGE>5
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF OPERATIONS

                                            For the nine   Nov 5, 1999
                                            months ended    (date of
                                              Sept 30,    inception) to
                                                2003      Sept 30, 2003
                                             ----------    ----------

Revenue                                      $        -    $        -
Expenses
  General and Administrative                     (1,213)      (51,762)
                                             ----------    ----------
Net (loss) before income taxes                   (1,213)      (51,762)
Current Tax Expense                                   -             -
Deferred Tax Expense                                  -             -
                                             ----------    ----------
  Net (loss)                                 $   (1,213)   $  (51,762)
                                             ==========    ==========
Loss Per Common Share                              (.00)         (.00)

The accompanying notes are an integral part of these financial
statements.

<PAGE>6
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A DEVELOPMENT STAGE COMPANY)
            CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
  FROM NOVEMBER 5, 1999 (DATE OF INCEPTION) THROUGH SEPTEMBER 30, 2003

                                    Preferred    Preferred       Common
                                      Stock        Stock        Stock
                                     Shares       Amount       Shares
                                   ----------   ----------   ----------
Balance, March 25, 1999                     -   $        -            -
Issuance of 1,000,000 shares
  common stock for cash
  at $.005 per share,
  December 1999                            -            -    1,000,000

Issuance of 50,000 Shares of
  common stock for cash at
  $.05 per share, December
  1999                                     -            -       50,000

Net (loss) for period                      -            -            -

Balance, December 31, 1999                 -            -    1,050,000

Issuance of 60,000 Shares of
  common stock for stock per
  reorganization agreement,
  May 2000                                 -            -       60,000

Net (loss) for period                      -            -            -
                                  ----------   ----------   ----------
Balance, December 31, 2000                 -            -    1,110,000

Net (loss) for Period                      -            -            -
                                  ----------   ----------   ----------
Balance, December 31, 2001                 -            -    1,110,000

Issuance of 4,200 Shares of
  common stock for cash at
  $.001 per share, May 2002                -            -        4,200

Net (loss) for Period                      -            -            -
                                  ----------   ----------   ----------
Balance, December 31, 2002                 -            -    1,114,200

Net (loss) for Period                      -            -            -
                                  ----------   ----------   ----------
Balance, September 30, 2003                -   $        -    1,114,200
                                  ==========   ==========   ==========

<PAGE>7
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A DEVELOPMENT STAGE COMPANY)
CONTINUED     CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
  FROM NOVEMBER 5, 1999 (DATE OF INCEPTION) THROUGH SEPTEMBER 30, 2003

                                    Common     Capital In
                                     Stock     Excess of   Accumulated
                                    Amount     Par Value    (Deficit)
                                  ----------   ----------   ----------

Balance, March 25, 1999                    -            -            -
Issuance of 1,000,000 shares
  common stock for cash
  at $.005 per share,
  December 1999                         1,000       4,000            -

Issuance of 50,000 Shares of
  common stock for cash at
  $.05 per share, December
  1999                                    50        2,450            -

Net (loss) for period                      -            -       (8,589)

Balance, December 31, 1999             1,050        6,450       (8,589)

Issuance of 60,000 Shares of
  common stock for stock per
  reorganization agreement,
  May 2000                                60       30,940            -

Net (loss) for period                      -            -      (29,239)
                                  ----------   ----------   ----------
Balance, December 31, 2000             1,110       37,390      (37,828)

Net (loss) for Period                      -            -       (5,398)
                                  ----------   ----------   ----------
Balance, December 31, 2001             1,110       37,390      (43,226)

Issuance of 4,200 Shares of
  common stock for cash at
  $.001 per share, May 2002                4        4,196            -

Net (loss) for Period                      -            -       (7,323)
                                  ----------   ----------   ----------
Balance, December 31, 2002             1,114       41,586      (50,549)

Net (loss) for Period                      -            -       (1,213)
                                  ----------   ----------   ----------
Balance, September 30, 2003       $    1,114       41,586      (51,762)
                                  ==========   ==========   ==========

The accompanying notes are an integral part of these financial
statements.

<PAGE>8
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A DEVELOPMENT STAGE COMPANY)
                CONSOLIDATED STATEMENTS OF CASH FLOWS
                   NET INCREASE (DECREASE) IN CASH

                                            For the nine   Nov 5, 1999
                                            months ended    (date of
                                              Sept 30,    inception) to
                                                2003      Sept 30, 2003
                                             ----------    ----------
Cash Flows Provided by  Operating Activities:
  Net Loss                                   $   (1,213)   $  (51,762)
  Adjustments to reconcile net loss to net
   cash used by operating activities:
    Bad debt expense                                  -        15,000
  Changes in assets and liabilities:
    Accounts payable                                  -        31,310
    Note payable - shareholder                        -         5,000
                                             ----------    ----------
  Net Cash Provided (Used) by Operating
   Activities                                    (1,213)         (452)

Cash Flows Provided by Investing Activities
  Payment for note receivable                         -       (15,000)
                                             ----------    ----------
    Net Cash Provided (Used) by Investing
     Activities                                       -       (15,000)

Cash Flows Provided by Financing Activities
  Proceeds from issuance of common stock              -        42,700
  Payments for stock offering costs                   -       (24,742)
                                             ----------    ----------
    Net Cash Provided (Used) by Financing
     Activities                                       -        17,958
    Net Increase (Decrease) in Cash              (1,213)        2,506
    Cash at Beginning of Period                   3,719             -
                                             ----------    ----------
    Cash at End of Period                    $    2,506    $    2,506

Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
  Interest                                   $        -    $        -
  Income taxes                               $        -    $        -

Supplemental Schedule of Noncash Investing and Financing Activities

From November 5, 1999 (date of Inception) through September 30, 2003:
Cancellation of 1,000,000 shares common stock per reorganization
agreement, with an offsetting credit to capital in excess of par value
of $1,000.

The accompanying notes are an integral part of these financial
statements.

<PAGE>9
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A DEVELOPMENT STAGE COMPANY)

              NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Business of the Company - Digitalpreviews.com, Inc.
("Parent") was organized under the laws of the State of Nevada on
November 5, 1999.  Dialaclass.com, Inc. ("Subsidiary") was organized
under the laws of the State of Nevada on March 26, 1999.  The initial
purpose of Intraop Medical Corporation and Subsidiary (the "Company")
was to engage in a consulting and seminar business.  The Company has
not generated any revenues  from its consulting and seminar business.
The Company is considered a development stage company as defined in
Statement of Financial Accounting Standards No. 7.  The Company has, at
the present time, not paid any dividends and any dividends that may be
paid in the future will depend upon the financial requirements of the
Company and other relevant factors.

Consolidation - The  consolidated financial statements include the
accounts of Parent and the wholly owned Subsidiary.  All significant
intercompany transactions have been eliminated in consolidation.

Stock Offering Costs - Costs related to proposed stock offerings are
deferred until the offering is completed and are offset against the
proceeds of the offering as a reduction to capital in excess of par
value.  In the event a stock offering is unsuccessful, the costs
related to the offering will be written-off directly to expense.

Revenue Recognition - The Company has not yet generated any revenue.

Interest Income - The Company recognizes interest income on impaired
loans in the period when payment is received.

Research and Development - Research and development costs are expensed
as incurred.

Loss Per Share - The computation of loss per share is based on the
weighted average number of shares outstanding during the period
presented in accordance with Statement of Financial Accounting
Standards No. 128, "Earnings Per Share".

Cash and Cash Equivalents - For purposes of the statement of cash
flows, the Company considers all highly liquid debt investments
purchased with a maturity of three months or less to be cash
equivalents.

Accounting Estimates - The preparation of consolidated financial
statements in conformity with generally accepted accounting principles
requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, the disclosures of
contingent assets and liabilities at the date of the consolidated
financial statements, and the reported amount of revenues and expenses
during the reported period.  Actual results could differ from those
estimated.

Recently Enacted Accounting Standards - Statement of Financial
Accounting Standards ("SFAS") No. 141, "Business Combinations", SFAS

<PAGE>10

No. 142, "Goodwill and Other Intangible Assets", SFAS No. 143,
"Accounting for Asset Retirement Obligations", and SFAS No. 144,
"Accounting for the Impairment or disposal of Long-Lived Assets", were
recently issued.  SFAS No. 141, 142, 143 and 144 have no current
applicability to the Company or their effect on the consolidated
financial statements would not have been significant.

NOTE 2 - BUSINESS REORGANIZATION

On May 1, 2000 the Company entered into an Agreement and Plan of
Reorganization wherein Parent acquired all the issued and outstanding
shares of common stock of Subsidiary in a stock for stock exchange.
Parent issued 60,000 shares of common stock in the exchange.  Parent
and Subsidiary had similar ownership at the time of reorganization and
were considered to be entities under common control.  Accordingly, the
reorganization has been recorded in a manner similar to a pooling of
interest.  The results of operations of Subsidiary have been included
in the consolidated financial statements since the date of inception of
Subsidiary.

NOTE 3 - IMPAIRED NOTE RECEIVABLE

On August 18, 2000 the Company signed a 30-day note receivable with
Thinmillionaire.com, Inc.  The Company loaned $15,000 to
Thinmillionaire.com, Inc. at 10 percent interest per annum.  As an
incentive, Thinmillionaire.com, Inc. has agreed to issue 3,000 shares
of common stock to the Company.

Thinmillionaire.com, Inc. defaulted on the note and a new note was
signed on January 5, 2001 for the outstanding principal and accrued
interest for a total of $15,579.  The new note was due June 5, 2001 and
accrued interest at 10 percent per annum.  As an incentive,
Thinmillionaire.com, Inc. has agreed to issue 6,000 shares of common
stock to the Company.

Thinmillionaire.com, Inc. defaulted on the new note receivable.

Thinmillionaire.com, Inc. does not currently have the resources to
repay the note and the note receivable is considered impaired.
Although the Company intends to continue its efforts to collect the
impaired note receivable, an allowance for doubtful accounts has been
accrued for the amount of the impaired note receivable and no interest
income has been recognized.  A bad debt expense of $15,000 was recorded
as part of general and administrative expense in December 2000.  A
summary of the impaired note receivable is as follows:

                                                        September 30,
                                                            2003
                                                         ----------
     Note  Receivable                                    $   15,000
    Less:  Allowance  for  Doubtful  Account                (15,000)
                                                         ----------
                                                         $

<PAGE>11

NOTE 4 - MANUSCRIPT AND TRANSCRIPTS

The Company paid $14,831 from January through December 2002 to
consultants to prepare a manuscript about online investing with
accompanying transcripts for audiotapes and a handbook.  The costs of
the manuscript and transcripts are considered research and are included
in general and administrative expense.

NOTE 5 - CAPITAL STOCK

Preferred Stock - The Company has authorized 5,000,000 shares of
preferred stock, $.001 par value, which such rights, preferences and
designations and to be issued in such series as determined by the Board
of Directors.  No shares are issued and outstanding at September 30,
2003.

Common Stock - During December 1999, in connection with its
organization, the Company issued 1,000,000 shares of its previously
authorized, but unissued common stock.  The shares were issued for cash
in the amount of $5,000 (or $.005 per share).

During December 1999, the Company issued 50,000 shares of its
previously authorized but unissued common stock.  The shares were
issued for cash in the amount of $2,500 (or $.05 per share).

During May 2000, in connection with the business reorganization, Parent
issued 60,000 shares of common stock in exchange for 60,000 shares of
Subsidiary common stock.

During May 2002, the Company issued 4,200 shares of its previously
authorized but unissued common stock.  The shares were issued for cash
in the amount of $4,200 (or $1.00 per share).

The Company authorized a 20 to 1 forward stock split, effective October
1, 2003, for the Company's outstanding common stock.  As of October 1,
2003, the outstanding shares of common stock increased from 1,114,200
shares to 22,284,000 shares.

NOTE 6 - INCOME TAXES

The Company accounts for income taxes in accordance with Statement of
Financial Accounting Standards No. 109 "Accounting for Income Taxes".
SFAS No. 109 requires the Company to provide a net deferred tax
asset/liability equal to the expected future tax benefit/expense of
temporary reporting differences between book and tax accounting methods
and any available operating loss or tax credit carry forwards.
The Company has available at September 30, 2003, unused operating loss
carry forwards of $51,762.  The amount of and ultimate realization of
the benefits from the operating loss carry forwards for income tax
purposes is dependent, in part, upon the tax laws in effect, the future
earnings of the Company, and other future events, the effects of which
cannot be determined.  Because of the uncertainty surrounding the
realization of the loss carry forwards, the Company has established a
valuation allowance equal to the tax effect of the loss carry forwards
and, therefore, no deferred tax asset has been recognized for the loss
carry forwards.

<PAGE>12

NOTE 7 - RELATED PARTY TRANSACTIONS

Management Compensation - As of September 30, 2003, the Company has not
paid any compensation to any officer or director of the Company.

Office Space - The Company has not had a need to rent office space.  An
officer / shareholder of the Company is allowing the Company to use his
office as a mailing address, as needed.  The cost is minimal and has
not been recorded as an expense of the Company.

NOTE 8 - GOING CONCERN

The accompanying consolidated financial statements have been prepared
in conformity with generally accepted accounting principals, which
contemplate continuation of the Company as a going concern.  However,
the Company has incurred losses since its inception and has not yet
been successful in establishing profitable operations.  Further, the
Company has current liabilities in excess of current assets.  These
factors raise substantial doubt about the ability of the Company to
continue as a going concern.  In this regard, management is proposing
to raise the necessary additional funds not provided by operations
through loans or through additional sales of their common stock.  There
is no assurance that the Company will be successful in raising this
additional capital or achieving profitable operations.  The
consolidated financial statements do not include any adjustments that
might result from the outcome of these uncertainties.

NOTE 9 - LOSS PER SHARE

The following data shows the amounts used in computing loss per share:

                                            For the nine   Nov 5, 1999
                                            months ended    (date of
                                              Sept 30,    inception) to
                                                2003      Sept 30, 2003
                                             ----------    ----------
Loss from Continuing operations available
  to common shareholders (numerator)         $        -   $   (51,762)

Weighted average of common Shares outstanding
  used in loss per share for the period
  (denominator)                               1,114,200     1,100,000

Dilutive loss per share was not presented, as the Company had no common
stock equivalent shares for all period presented that would affect the
computation of diluted loss per share.

NOTE 10 - SUBSEQUENT EVENTS

On October 3, 2003 certain of the Company's shareholders agreed to sell
to Peyton, Chander & Sullivan, Inc. ("PCS") and its assigns 2,264,735
shares of the Company's Common Stock representing approximately 10
percent of the Company's outstanding Common Stock.  On December 15,
2003, the Company entered into a non-binding letter of intent to merge
with Intraop Medical, Inc.  On December 30, 2003 Digitalpreviews.com

<PAGE>13

has changed its name to Intraop Medical Corporation.  The Company is
currently negotiating the definitive merger agreement.  The Company has
discontinued all of its business operations.

The Company authorized a 20 to 1 forward stock split, effective October
1, 2003, for the Company's outstanding common stock.  As of October 1,
2003, the outstanding shares of common stock increased from 1,114,200
shares to 22,284,000 shares.

On October 1, 2003, the Company spun-off its wholly-owned subsidiary,
Dialaclass.com, Inc., to its shareholders of record on October 1, 2003
by dividending to such stockholders all of the shares of
Dialaclass.com, Inc.  At the time of the spin-off Dialaclass.com, Inc.
had no operations or assets.

<PAGE>14
              INTRAOP  MEDICAL CORPORATION AND SUBSIDIARY
                      (A Development Stage Company)

CONTENTS

                                                          Page Number
                                                         -------------
    Unaudited Condensed Consolidated Balance Sheets,
     September 30, 2002 and December 31, 2001                  F - 10

    Unaudited Condensed Consolidated Statements of
     Operations, for the three and nine months ended
     September 30, 2002 and 2001 and for the period
     from inception on November 5, 1999 through
     September 30, 2002                                        F - 11

    Unaudited Condensed Consolidated Statements of
     Cash Flows, for the nine months ended
     September 30, 2002 and 2001 and for the period
     from inception on November 5, 1999 through
     September 30, 2002                                        F - 12

    Notes to Unaudited Condensed Consolidated
     Financial Statements                                      F - 13

<PAGE>15
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A Development Stage Company)

            UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

                                ASSETS
                                               Sept 30,      Dec 31,
                                                 2002         2001
                                              ----------   ----------
CURRENT ASSETS:
  Cash                                        $    7,570   $    1,842
                                              ----------   ----------
    Total Current Assets                           7,570        1,842
                                              ----------   ----------
OTHER ASSETS:
  Impaired note receivable, net(See Note 3)            -            -
  Deferred stock offering costs                    13,282      12,982
                                              ----------   ----------
    Total Other Assets                            13,282       12,982
                                              ----------   ----------
                                              $   20,852   $   14,824
                                              ==========   ==========

             LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES:
  Accounts payable                            $   28,890   $   19,550
  Advance from a shareholder                       2,500            -
                                              ----------   ----------
    Total Current Liabilities                     31,390       19,550
                                              ----------   ----------

STOCKHOLDERS' EQUITY (DEFICIT):
  Preferred stock, $.001 par value,
   5,000,000 shares authorized, no shares
   issued and outstanding                              -            -
  Common stock, $.001 par value,
   50,000,000 shares authorized,
   1,114,200 and 1,110,000 shares
   issued and outstanding, respectively            1,114        1,110
  Capital in excess of par value                  41,586       37,390
  Deficit accumulated during the
   development stage                             (53,238)     (43,226)
                                              ----------   ----------
    Total Stockholders' Equity (Deficit)         (10,538)      (4,726)
                                              ----------   ----------
                                              $   20,852   $   14,824
                                              ==========   ==========

NOTE:   The balance sheet at December 31, 2001 was taken from the
audited financial  statements at that date and condensed.

The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.

<PAGE>16
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A Development Stage Company)

       UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
                                                                             From
                                                                          Inception On
                                                                          Nov 5, 1999
                        For the Three Months       For the Nine Months      Through
                         Ended September 30,       Ended September 30,      Sept 30,
                          2002         2001         2002         2001         2002
                       ----------   ----------   ----------   ----------   ----------
                    <c>          <c>          <c>          <c>          <c>
REVENUE                $        -   $        -   $        -   $        -   $        -
EXPENSES:
  General and
   administrative           1,806        1,123       10,012        3,715       53,238
                       ----------   ----------   ----------   ----------   ----------
LOSS BEFORE INCOME TAXES (  1,806)      (1,123)     (10,012)      (3,715)     (53,238)
CURRENT TAX EXPENSE             -            -            -            -            -
DEFERRED TAX EXPENSE            -            -            -            -            -
                       ----------   ----------   ----------   ----------   ----------
NET LOSS               $   (1,806)  $   (1,123)  $  (10,012)  $   (3,715)  $  (53,238)
                       ==========   ==========   ==========   ==========   ==========

LOSS PER COMMON SHARE  $     (.00)  $     (.00)  $     (.01)  $     (.00)  $     (.05)
                       ==========   ==========   ==========   ==========   ==========
</TABLE>

The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.

<PAGE>17
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A Development Stage Company)

       UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

                    NET INCREASE (DECREASE) IN CASH
                                                              From
                                                            Inception
                                                            on Nov 5,
                                    For the Nine Months     1999 Thru
                                     ended September 30,     Sept 30,
                                     2002         2001         2002
                                  ----------   ----------   ----------
Cash Flows From Operating Activities:
Net loss                          $  (10,012)  $   (3,715)  $  (53,238)
Adjustments to reconcile net
 loss to net cash provided (used)
 by operating activities:
Bad debt expense                           -            -       15,000
Changes in assets and liabilities:
  Increase in accounts payable         9,340        2,708       28,890
    Net Cash Provided (Used) by
     Operating Activities               (672)     ( 1,007)      (9,348)
                                  ----------   ----------   ----------
Cash Flows From Investing Activities:
  Payments for note receivable             -            -      (15,000)
    Net Cash (Used) by Investing
     Activities                            -            -      (15,000)
                                  ----------   ----------   ----------
Cash Flows From Financing Activities:
  Advances from a shareholder          2,500            -        2,500
  Proceeds from issuance of common
   stock                               4,200            -       42,700
  Payments for stock offering costs     (300)           -      (13,282)
                                  ----------   ----------   ----------
    Net Cash Provided by Financing
     Activities                        6,400            -       31,918
                                  ----------   ----------   ----------
Net Increase (Decrease) in Cash        5,728       (1,007)       7,570
Cash at Beginning of Period            1,842        3,072            -
                                  ----------   ----------   ----------
Cash at End of Period             $    7,570   $    2,065   $    7,570
                                  ==========   ==========   ==========
Supplemental Disclosures of Cash
 Flow Information:
Cash paid during the period for:
Interest                          $        -   $        -   $        -
Income taxes                      $        -   $        -   $        -

Supplemental Schedule of Noncash
 Investing and Financing Activities:
    For the nine months ended September 30, 2002:
         None
    For the nine months ended September 30, 2001:
         None

The accompanying notes are an integral part of these unaudited
condensed consolidated financial statements.

<PAGE>18
              INTRAOP MEDICAL CORPORATION AND SUBSIDIARY
                      (A Development Stage Company)

    NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Business of the Company - Digitalpreviews.com, Inc.
("Parent") was organized under the laws of the State of Nevada on
November 5, 1999.  Dialaclass.com, Inc. ("Subsidiary") was organized
under the laws of the State of Nevada on March 26, 1999.  The initial
purpose of Intraop Medical Corporation and Subsidiary (the "Company")
was to engage in a consulting and seminar business.  The Company has
not generated any revenues  from its consulting and seminar business.
The Company is considered a development stage company as defined in
Statement of Financial Accounting Standards No. 7.  The Company has, at
the present time, not paid any dividends and any dividends that may be
paid in the future will depend upon the financial requirements of the
Company and other relevant factors.

Condensed Financial Statements - The accompanying financial statements
have been prepared by the Company without audit.  In the opinion of
management, all adjustments (which include only normal recurring
adjustments) necessary to present fairly the financial position,
results of operations and cash flows at September 30, 2002 and 2001 and
for the periods then ended have been made.

Certain information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted
accounting principles in the United States of America have been
condensed or omitted.  It is suggested that these condensed financial
statements be read in conjunction with the financial statements and
notes thereto included in the Company's December 31, 2001 audited
financial statements.  The results of operations for the periods ended
September 30, 2002 and 2001 are not necessarily indicative of the
operating results for the full year.

Consolidation - The consolidated financial statements include the
accounts of Parent and the wholly owned Subsidiary.  All significant
intercompany transactions have been eliminated in consolidation.
Cash and Cash Equivalents - The Company considers all highly liquid
debt investments purchased with a maturity of three months or less to
be cash equivalents.

Accounts and Loans Receivable - The Company records accounts and loans
receivable at the lower of cost or fair value.  The Company determines
the lower of cost or fair value of non-mortgage loans on an individual
asset basis.  The Company recognizes interest income on an account
receivable based on the stated interest rate for past-due accounts over
the period that the account is past-due.  The Company recognizes
interest income on a loan receivable based on the stated interest rate
over the term of the loan.  The Company accumulates and defers fees and
costs associated with establishing a receivable to be amortized over
the estimated life of the related receivable.  The Company estimates
allowances for doubtful accounts and loan losses based on the aged
receivable balance and historical losses.  The Company records interest
income on delinquent accounts and loans receivable only when payment is
received.  The Company first applies payments received on delinquent
accounts and loans receivable to eliminate the outstanding principal.

<PAGE>19

The Company charges off uncollectible accounts and loans receivable
when management estimates no possibility of collecting the related
receivable.  The Company considers accounts and loans receivable to be
past-due or delinquent based on contractual terms.

Stock Offering Costs - Costs related to proposed stock offerings are
deferred until the offering is completed and are offset against the
proceeds of the offering as a reduction to capital in excess of par
value.  In the event a stock offering is unsuccessful, the costs
related to the offering will be written-off directly to expense.

Revenue Recognition - The Company has not yet generated any revenue.

Research and Development - Research and development costs are expensed
as incurred.

Loss Per Share - The computation of loss per share is based on the
weighted average number of shares outstanding during the period
presented in accordance with Statement of Financial Accounting
Standards No. 128, "Earnings Per Share".  (See Note 9)

Accounting Estimates - The preparation of financial statements in
conformity with generally accepted accounting principles in the United
States of America requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, the
disclosures of contingent assets and liabilities at the date of the
financial statements, and the reported amount of revenues and expenses
during the reported period.  Actual results could differ from those
estimated.

Recently Enacted Accounting Standards - Statement of Financial
Accounting Standards ("SFAS") No. 141, "Business Combinations", SFAS
No. 142, "Goodwill and Other Intangible Assets", SFAS No. 143,
"Accounting for Asset Retirement Obligations", SFAS No. 144,
"Accounting for the Impairment or Disposal of Long-Lived Assets", SFAS
No. 145, "Rescission of FASB Statements No. 4, 44, and 64, Amendment of
FASB Statement No. 13, and Technical Corrections", SFAS No. 146,
"Accounting for Costs Associated with Exit or Disposal Activities", and
SFAS No. 147, "Acquisitions of Certain Financial Institutions - an
Amendment of FASB Statements No. 72 and 144 and FASB Interpretation No.
9", were recently issued.  SFAS No. 141, 142, 143, 144, 145, 146 and
147 have no current applicability to the Company or their effect on the
financial statements would not have been significant.

NOTE 2 - BUSINESS REORGANIZATION

On May 1, 2000, the Company entered into an agreement and plan of
reorganization wherein Parent acquired all the issued and outstanding
shares of common stock of Subsidiary in a stock for stock exchange.
Parent issued 60,000 shares of common stock in the exchange.  Parent
and Subsidiary had similar ownership at the time of reorganization and
were considered to be entities under common control. Accordingly, the
reorganization has been recorded in a manner similar to a pooling of
interest.  The results of operations of Subsidiary have been included
in the consolidated financial statements since the date of inception of
Subsidiary.

<PAGE>20

NOTE 3 - IMPAIRED NOTE RECEIVABLE

On August 18, 2000 the Company signed a 30-day note receivable with
Thinmillionaire.com, Inc.  The Company loaned $15,000 to
Thinmillionaire.com, Inc. at 10 percent interest per annum.  As an
incentive, Thinmillionaire.com agreed to issue 3,000 shares of common
stock to the Company.

Thinmillionaire.com, Inc. defaulted on the note and a new note was
signed on January 5, 2001 for the outstanding principal and accrued
interest for a total of $15,579.  The new note was due June 5, 2001 and
accrued interest at 10 percent per annum.  As an incentive,
Thinmillionaire.com agreed to issue 6,000 shares of common stock to the
Company.

Thinmillionaire.com, Inc. defaulted on the new note receivable.

Thinmillionaire.com does not currently have the resources to repay the
note and the note receivable is considered impaired.  Although the
Company intends to continue its efforts to collect the impaired note
receivable, an allowance for doubtful accounts has been accrued for the
amount of the impaired note receivable and no interest income has been
recognized.  A bad debt expense of $15,000 was recorded as part of
general and administrative expense in December 2000.  A summary of the
impaired note receivable is as follows:

                                               Sept 30,      Dec 31,
                                                 2002         2001
                                              ----------   ----------
    Note Receivable                           $   15,000   $   15,000
    Less: Allowance for Doubtful Account         (15,000)     (15,000)
                                              ----------   ----------
                                              $        -   $        -

NOTE 4 - MANUSCRIPT AND TRANSCRIPTS

The company paid $9,831 from January through May 2000 to consultants to
prepare a manuscript about online investing with accompanying
transcripts for audio tapes and a handbook.  The costs of the
manuscript and transcripts are considered research and are included in
general and administrative expense.

NOTE 5 - CAPITAL STOCK

Preferred Stock - The Company has authorized 5,000,000 shares of
preferred stock, $.001 par value, with such rights, preferences and
designations and to be issued in such series as determined by the Board
of Directors. No shares are issued and outstanding at September 30,
2002 and December 31, 2001.

Common Stock - The Company has authorized 50,000,000 shares of common
stock with a $.001 par value.  During December 1999, in connection with
its organization, the Company issued 1,000,000 shares of its previously
authorized, but unissued common stock.  The shares were issued for cash
of $5,000 (or $.005 per share).

During December 1999, the Company issued 50,000 shares of its
previously authorized but unissued common stock.  The shares were
issued for cash in the amount of $2,500 (or $.05 per share).

<PAGE>21

During May 2000, in connection with the business reorganization, Parent
issued 60,000 shares of common stock in exchange for 60,000 shares of
Subsidiary common stock.

During May 2002, the Company sold 4,200 units as part of a public
offering of 125,000 units at $1.00 per unit.  Each unit consists of one
share of the Company's previously authorized but unissued common stock,
one Class A warrant and one Class B warrant.  Class A warrants can be
exercised at $2.50 per share and expire December 31, 2003.  Class B
warrants can be exercised at $5.00 per share and expire December 31,
2003.  Stock offering costs estimated to be $16,250 will be offset
against the proceeds of the offering in capital in excess of par value
at the close of the offering.

Stock Warrants - During May 2002, the Company issued 4,200 Class A
warrants and 4,200 Class B warrants as part of a public offering.
Class A warrants can be exercised at $2.50 per share and expire
December 31, 2003.  Class B warrants can be exercised at $5.00 per
share and expire December 31, 2003.  At September 30, 2002, there are
4,200 Class A warrants and 4,200 Class B warrants outstanding.

NOTE 6 - INCOME TAXES

The Company accounts for income taxes in accordance with Statement of
Financial Accounting Standards No. 109 "Accounting for Income Taxes".
SFAS No. 109 requires the Company to provide a net deferred tax
asset/liability equal to the expected future tax benefit/expense of
temporary reporting differences between book and tax accounting methods
and any available operating loss or tax credit carryforwards.
The Company has available at September 30, 2002 unused operating loss
carryforwards of approximately $53,200 which may be applied against
future taxable income and which expire in various years through 2022.
The amount of and ultimate realization of the benefits from the
operating loss carryforwards for income tax purposes is dependent, in
part, upon the tax laws in effect, the future earnings of the Company,
and other future events, the effects of which cannot be determined.
Because of the uncertainty surrounding the realization of the loss
carryforwards, the Company has established a valuation allowance equal
to the tax effect of the loss carryforwards and, therefore, no deferred
tax asset has been recognized for the loss carryforwards.  The net
deferred tax assets are approximately $16,200 and $14,500 as of
September 30, 2002 and December 31, 2001, respectively, with an
offsetting valuation allowance of the same amount, resulting in a
change in the valuation allowance of approximately $1,700 during the
nine months ended September 30, 2002.

NOTE 7 - RELATED PARTY TRANSACTIONS

Management Compensation - As of September 30, 2002, the Company has not
paid any compensation to any officer or director of the Company.
Office Space - The Company has not had a  need to rent office space.
An officer/shareholder of the Company is allowing the Company to use
his office as a  mailing address, as needed.  The cost is minimal and
has not been recorded as an expense of the company.

<PAGE>22

NOTE 8 - GOING CONCERN

The accompanying financial statements have been prepared in conformity
with generally accepted accounting principles in the United States of
America, which contemplate continuation of the Company as a going
concern.  However, the Company has incurred losses since its inception
and has not yet been successful in establishing profitable operations.
Further, the Company has current liabilities in excess of current
assets.  These factors raise substantial doubt about the ability of the
Company to continue as a going concern.  In this regard, management is
proposing to raise any necessary additional funds not provided by
operations through loans or through additional sales of their common
stock.  There is no assurance that the Company will be successful in
raising this additional capital or achieving profitable operations.
The financial statements do not include any adjustments that might
result from the outcome of these uncertainties.

NOTE 9 - LOSS PER SHARE

The following data shows the amounts used in computing loss per share:
<TABLE>
<CAPTION>
                                                                             From
                                                                          Inception On
                                                                          Nov 5, 1999
                        For the Three Months       For the Nine Months      Through
                         Ended September 30,       Ended September 30,      Sept 30,
                          2002          2001        2002         2001        2002
                       ----------   ----------   ----------   ----------   ----------
                    <c>          <c>          <c>          <c>          <c>
Loss from continuing
 operations available
 to common shareholders
 (numerator)           $   (1,806)  $   (1,123)  $  (10,012)  $   (3,715)  $  (53,238)

Weighted average number
 of common shares
 outstanding used in
 loss per share for the
 period (denominator)   1,114,200    1,110,000    1,112,308    1,110,000    1,100,151
</TABLE>

At September 30, 2002, the Company had 4,200 outstanding Class A
warrants and 4,200 outstanding Class B warrants which were not used in
the computation of loss per share because their effect would be anti-
dilutive.  Dilutive loss per share was not presented, as the Company
had no common stock equivalent shares for all periods presented that
would affect the computation of diluted loss per share.

NOTE 10 - SUBSEQUENT EVENTS

The Company has discontinued all of its business operations.  On
October 3, 2003 certain of the Company's shareholders agreed to sell to
Peyton, Chander & Sullivan, Inc. ("PCS") and its assigns 2,264,735
shares of the Company's Common Stock representing approximately 10
percent of the Company's outstanding Common Stock.  On December 15,
2003, the Company entered into a non-binding letter of intent to merge

<PAGE>23

with Intraop Medical, Inc.  On December 30, 2003 Digitalpreviews.com
has changed its name to Intraop Medical Corporation.  The Company is
currently negotiating the definitive merger agreement.

Item 2.  Management's Discussion and Analysis or Plan of Operations

               FORWARD LOOKING AND CAUTIONARY STATEMENTS

Except for the historical information and discussions contained herein,
statements contained in this Form 10-QSB/A may constitute "forward
looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995.  These statements involve a number of
risks, uncertainties and other factors that could cause actual results
to differ materially, including the company's ability to raise
operating capital through the sale of equity securities; to
successfully launch its products into the market and other risks,
uncertainties and factors discussed elsewhere in this Form 10-QSB/A or
in the Company's other filings with the Securities and Exchange
Commission.

                          PLAN OF OPERATIONS

In September 2003, Intraop Medical Corporation (formerly
Digitalpreviews.com), in anticipation of negotiating a potential merger
with an operating company, formally abandoned its consulting and
seminar business operations.  On September 25, 2003 the Board of
Directors has approved a 20:1 share dividend to the holders of the
Company's Common Stock.  As result, as of the date of this filing, the
number of shares outstanding was 20,284,000 Shares of $0.001 par value
Common Stock.  On October 3, 2003 certain of the Company's shareholders
agreed to sell to PCS and its assigns 2,264,735 shares of the Company's
Common Stock representing approximately 10 percent of the Company's
outstanding Common Stock.  On December 15, 2003, the Company entered
into a non-binding letter of intent to merge with Intraop Medical, Inc.
On December 30, 2003 Digitalpreviews.com has changed its name to
Intraop Medical Corporation.  The Company is currently negotiating the
definitive merger agreement.  There can be no assurances that the
agreement will be executed or, if executed, will be approved by the
constituent company stockholders or that the proposed merger will ever
occur.

In the event the merger is completed, it is expected that up to
approximately 14.2 million shares of the Company's common stock and
approximately 1.5 million shares of combined warrants and options  will
be issued to Intraop Medical Inc. stockholders, convertible note
holders, option holders, warrant holders and service providers as of
the closing date of the merger and that 19,982,265 shares currently
owned of record by David Shamy will be cancelled, resulting in
approximately  95 percent of the Company, on a fully diluted basis,
being held by Intraop Medical, Inc. stockholders, convertible note
holders, optionholders, warrant holders, and service providers as of
the closing date (including shares held by such service providers prior
to the closing of the merger).  Further, if the merger is completed the
business of the Company will be the business of Intraop Medical Inc.
It is expected that before or after completion of the merger the
Company may seek additional equity investment, resulting in further
dilution to current shareholders.

<PAGE>24

In the event the merger is not completed, the Company may potentially
seek another merger partner or may go out of business.  The Company
does not have the resources to operate a business without acquiring one
by way of merger.  The 19,982,265 shares held by Shamy subject to
cancellation may be cancelled at any time by the Company if the
proposed merger is not completed.

Item 3.  Controls And Procedures.

As required by Rule 13a-15 under the Securities Exchange Act of 1934
(the "Exchange Act"), we carried out an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures
within the 90 days prior to the filing date of this report.  This
evaluation was carried out under the supervision and with the
participation of our Chief Executive Officer and Chief Financial
Officer, Mr. David Shamy.  Based upon that evaluation, our Chief
Executive Officer and Chief Financial Officer concluded that our
disclosure controls and procedures are effective in timely alerting
management to material information relating to us required to be
included in our periodic SEC filings.  There have been no significant
changes in our internal controls or in other factors that could
significantly affect internal controls subsequent to the date we
carried out our evaluation.

Disclosure controls and procedures are controls and other procedures
that are designed to ensure that information required to be disclosed
our reports filed or submitted under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified
in the Securities and Exchange Commission's rules and forms.
Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information required to
be disclosed in our reports filed under the Exchange Act is accumulated
and communicated to management, including our Chief Executive Officer
and Chief Financial Officer, to allow timely decisions regarding
required disclosure.

                      PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is not a party to any material legal proceedings and to our
knowledge, no such proceedings are threatened or contemplated.

Item 2.  Changes in Securities

The Company did not complete any sales of our securities during the
fiscal quarter ended September 30, 2003.

Item 3.  Defaults upon Senior Securities

None.

Item 4.  Submission of Matters to a Vote of Security Holders

None.

<PAGE>25

Item 5.  Other Information

None.

Item 6.  Exhibits and Reports on Form 8-K.

EXHIBITS

    Exhibit Number        Description
        4.1            Agreement for the Purchase of Common Stock
                       dated October 3, 2003

       99.1            Certification by CEO and CFO pursuant to 18
                       U.S.C. Section 1350, as adopted pursuant to
                       Section 906 of the Sarbanes-Oxley Act of 2002.

REPORTS ON FORM 8-K

The Company did not file any Current Reports on Form 8-K during the
fiscal quarter ended September 30, 2003.  The Company did subsequently
file on January 8, 2004, a Current Report on Form 8-K dated December
30, 2003 (the "8-K Report").  In the 8-K Report the Company has
reported the following items:

i)   On December 15, 2003, Digitalpreviews.com, Inc. entered into a
non-binding letter of intent ("LOI") with Introp Medical, Inc. by which
Intraop Medical, Inc. would sell, merge, consolidate, or otherwise
transfer all of its assets, liabilities and business operations to
Digitalpreviews.com, Inc.  The 8-K Report indicated that the LOI was
subject to the completion of a definitive merger agreement and
shareholder approval.

ii)  On December 30, 2003, a Certificate of Amendment was filed with
the state of Nevada to change the name of the Company to Intraop
Medical Corporation.

<PAGE>26
                               SIGNATURES

In accordance with the requirements of the Securities and Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                       INTRAOP MEDICAL CORPORATION

                                       Date:  February 24, 2004

                                       By:    /s/   David Shamy
                                       David Shamy
                                       Principal Executive Officer
                                       Principal Financial Officer
                                       Chief Accounting Officer

   CERTIFICATION PURSUANT TO RULE 13a-14 OR 15d-14 OF THE SECURITIES
    EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE
                      SARBANES-OXLEY ACT OF 2002

I, David Shamy, Principal Executive Officer and Principal Financial
Officer of Intraop Medical Corporation (formerly Digitalpreviews.com,
Inc.) (the "Registrant"), certify that:

  (1)  I have reviewed this quarterly report on Form10-QSB/A of Intraop
Medical Corporation (formerly Digitalpreviews.com, Inc.);

  (2)  Based on my knowledge, this quarterly report does not contain
any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this quarterly report;

  (3)  Based on my knowledge, the financial statements, and other
financial information included in this quarterly report, fairly present
in all material respects the financial condition, results of operations
and cash flows of the Registrant as of, and for, the periods presented
in this quarterly report;

  (4)  The Registrant's other certifying officers and I are responsible
for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and
have:
     a)  designed such disclosure controls and procedures to ensure
that material information relating to the Registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this quarterly report
is being prepared;
     b)  evaluated the effectiveness of the Registrant's disclosure
controls and procedures as of a date within 90 days prior to the filing
date of this quarterly report (the "Evaluation Date"); and
     c)  presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;

  (5)  The Registrant's other certifying officers and I have disclosed,
based on our most recent evaluation, to the Registrant's auditors and
the audit committee of Registrant's board of directors (or persons
performing the equivalent functions):
     a)  all significant deficiencies in the design or operation of
internal controls which could adversely affect the Registrant's ability
to record, process, summarize and report financial data and have
identified for the Registrant's auditors any material weaknesses in
internal controls; and
     b)  any fraud, whether or not material, that involves management
or other employees who have a significant role in the Registrant's
internal controls; and

<PAGE>28

  (6)  The Registrant's other certifying officers and I have indicated
in this quarterly report whether or not there were significant changes
in internal controls or in other facts that could significantly affect
internal controls subsequent to the date of our most recent evaluation,
including any corrective actions with regard to significant
deficiencies and material weaknesses.

                                         /s/   David Shamy
                                           David Shamy
                                           Principal Executive Officer
                                           Principal Financial Officer

                                           Date:  February 24, 2004

A signed original of this written statement required by Section 906 has
been provided to Intraop Medical Corporation and will be retained by
Intraop Medical Corporation and furnished to the Securities and
Exchange Commission or its staff upon request.

	F-28

	F-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]